Herpes zoster ophthalmicus or Herpes zoster maxillaris?

Chandravanshi, Shivcharan Lal; Rathore, MK

doi:10.4103/0301-4738.45517

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other findings included anterior uveitis, iritis, and anterior scleritis. These findings, which occurred in both healthy and immunocompromised patients, occurred in the acute phase or several weeks to months later [ 12 , 24 , 25 , 38 , 42 , 44 , 46 – 49 , 53 ]. Some patients were asymptomatic [ 24 ].…”

Section: Clinical Presentationmentioning

confidence: 99%

Pediatric herpes zoster ophthalmicus: a systematic review

Hakim

Riaz

Farooq

2023

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose While typically affecting older adults and immunocompromised individuals, herpes zoster ophthalmicus (HZO) has been reported with varying manifestations and complications in children. In this review, we evaluate reported cases of pediatric HZO in the literature and discuss the epidemiology, risk factors, clinical presentation, treatment and outcomes. Methods A literature search on PubMed, Scopus, and Web of Science databases was performed using the terms “pediatric herpes zoster ophthalmicus” and “herpes zoster ophthalmicus children.” Publications that were not specific to HZO or pediatric populations were excluded, as were publications that were not available to review or not published in the English language. Results Fifty-seven reports describing 130 cases of HZO or HZO-related complications were reviewed. Major risk factors for pediatric HZO included intrauterine exposure to varicella or primary varicella infection at a young age; HZO also occurred in patients who had received varicella vaccination. Both healthy and immunocompromised children were affected, with the majority of affected children being immunocompetent. The diagnosis of HZO is primarily clinical. Children appear to have good vision recovery and resolution of symptoms if they are treated promptly and if they adhere to treatment regimens, except for irreversible vision loss related to uncommon complications such as optic neuritis. Conclusion HZO occurs in both healthy and immunocompromised children. Recognizing this treatable condition is essential for reducing ocular and systemic morbidity. Long-term follow-up and assessments of the impact on health in adulthood are lacking. More systematic study is needed to determine the incidence of HZO in children and appropriate diagnostic and treatment protocols for the care of pediatric patients with HZO.

show abstract